Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study

İbrahim V. Bayoglu; Ibrahim Yildiz; Umut Varol; Suna Cokmert; Ahmet AlacacIoğlu; Yuksel Kucukzeybek; Murat Akyol; Lutfiye Demir; Ahmet Dirican; Oktay Tarhan

doi:10.5114/wo.2015.53374

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2015
vol. 19

Send email

Copy url:

abstract:

Original paper

Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study

İbrahim V. Bayoglu

,

Ibrahim Yildiz

,

Umut Varol

,

Suna Cokmert

,

Ahmet AlacacIoğlu

,

Yuksel Kucukzeybek

,

Murat Akyol

,

Lutfiye Demir

,

Ahmet Dirican

,

Oktay Tarhan

Contemp Oncol (Pozn) 2015; 19: 385-390

DOI: https://doi.org/10.5114/wo.2015.53374

Online publish date: 2015/08/13

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bayoglu İ, Yildiz I, Varol U, et al. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemporary Oncology/Współczesna Onkologia. 2015;19(5):385-390. doi:10.5114/wo.2015.53374.

APA

Bayoglu, İ., Yildiz, I., Varol, U., Cokmert, S., AlacacIoğlu, A.,  & Kucukzeybek, Y. et al. (2015). Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemporary Oncology/Współczesna Onkologia, 19(5), 385-390. https://doi.org/10.5114/wo.2015.53374

Chicago

Bayoglu, İbrahim V., Ibrahim Yildiz, Umut Varol, Suna Cokmert, Ahmet AlacacIoğlu, Yuksel Kucukzeybek,  and Murat Akyol et al. 2015. "Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study". Contemporary Oncology/Współczesna Onkologia 19 (5): 385-390. doi:10.5114/wo.2015.53374.

Harvard

Bayoglu, İ., Yildiz, I., Varol, U., Cokmert, S., AlacacIoğlu, A., Kucukzeybek, Y., Akyol, M., Demir, L., Dirican, A.,  and Tarhan, O. (2015). Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemporary Oncology/Współczesna Onkologia, 19(5), pp.385-390. https://doi.org/10.5114/wo.2015.53374

MLA

Bayoglu, İbrahim V. et al. "Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study." Contemporary Oncology/Współczesna Onkologia, vol. 19, no. 5, 2015, pp. 385-390. doi:10.5114/wo.2015.53374.

Vancouver

Bayoglu İ, Yildiz I, Varol U, Cokmert S, AlacacIoğlu A, Kucukzeybek Y et al. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemporary Oncology/Współczesna Onkologia. 2015;19(5):385-390. doi:10.5114/wo.2015.53374.

PlumX metrics:

Aim of the study: Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents.

Material and methods: This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/md1–5 in combination with leucovorin 90 mg/day, d1–5 followed by two days’ rest.

Results: The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2–24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6–4.6 months) and overall survival was 6.6 months (95% CI, 4.5–8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions.

Conclusions: This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.

keywords:

Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study

İbrahim V. Bayoglu , Ibrahim Yildiz , Umut Varol , Suna Cokmert , Ahmet AlacacIoğlu , Yuksel Kucukzeybek , Murat Akyol , Lutfiye Demir , Ahmet Dirican , Oktay Tarhan

uracil/tegafur, metastatic colorectal cancer, heavily pretreated, salvage therapy

İbrahim V. Bayoglu

,

Ibrahim Yildiz

,

Umut Varol

,

Suna Cokmert

,

Ahmet AlacacIoğlu

,

Yuksel Kucukzeybek

,

Murat Akyol

,

Lutfiye Demir

,

Ahmet Dirican

,

Oktay Tarhan